Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps
1. TRVI reported Phase 2a trial results for Haduvio with significant cough reduction. 2. Haduvio achieved 67% reduction in cough frequency; 84% of patients showed improvement. 3. Safety profile was consistent with previous trials; no serious adverse events reported. 4. Stock jumped 40.2% to $6.03 following positive trial results. 5. Topline results for Phase 2b trial expected in early 2025.